Articles

Sprint Bioscience has entered into a research collaboration with the Experimental Drug Development Centre (EDDC) in Singapore to expand Sprint Bioscience's MASH (Metabolic dysfunction-associated steatohepatitis) program into inflammatory diseases. Under the collaboration, compounds developed by Sprint Bioscience in the program will be evaluated by EDDC - Singapore's national platform for drug discovery and development and part of the...

In our work to develop small-molecule preclinical drug candidates that can contribute to new cancer therapies, speed and precision are crucial. By collaborating with SciLifeLab's Drug Discovery and Development (DDD) Platform, we gain access to advanced protein quality analysis - a key component of our fragment-based drug development. This infrastructure enables us to...

On April 8, the subscription period for Sprint Bioscience's rights issue began. The subscription rights are traded on First North Premier Growth Market until April 17, 2025, and the subscription period continues until April 24, 2025. More information can be found here. Read BioStock's interview (in Swedish) with CEO Johan Emilsson about the ongoing rights issue. See the latest Company Presentation, in the studio at [...]

Sprint Bioscience summarizes below its upcoming meetings with potential partners and investors. International partnering and investor conferences: September 18-19: Nordic Life Science Days, Malmö, Sweden October 8-9: LSX Nordic Congress, Copenhagen, Denmark November 4-6: BIO-Europe Stockholm, Sweden November 20-21: BioStock Life Science Summit

The Bio International Convention partnering conference was held June 3-6 in San Diego, California. Sprint Biosciences CEO Johan Emilsson was there. What general impressions do you take home from the conference? "It is almost always high pressure at this conference. It is one of the largest and most prestigious partnering conferences in biotechnology and drug development with...

Sprint Bioscience summarizes below its upcoming meetings with potential partners and investors. International partnering and investor conferences: March 18-20, 2024: BIO-Europe Spring, Barcelona, Spain April 29-30, 2024: LSX World Congress, London, England June 3-6, 2024: BIO International Convention, San Diego, USA 

Following the press release on December 15 regarding the Vps34 program, Redeye's analysts ask some questions to Sprint Biosciences CEO, Johan Emilsson. The interview is also available at Redeye. Why is Deciphera returning the program? According to the agreement, they have the right to return the program without specifying any reason and they have chosen not to go public with the reason. May this...

Johan Emilsson, newly appointed CEO of Sprint Bioscience, answers questions #femsnabba at Börsvärlden about the company's success in a tough, competitive market. The company is driven by demonstrating how effective drug development can be with the right attitude and skills, and by improving the lives of those affected by cancer. Johan Emilsson, you are the new CEO of Sprint Bioscience since [...]

See what has been written about Sprint Bioscience regarding the news of the VADA agreement: Fierce BiotechDaily IndustryBusiness WorldBioStock Börsronden v 33Pharmaceutical market - industry coverage from Dagens MedicinLifeScience SwedenNordic Life Science News

Sprint Biosciences acting CEO Mathias Skalmstad visited Redeye's studio and answered questions regarding the license agreement for the VADA program. Press releaseComment from Redeye on the agreement